Cystic Fibrosis Trust

Last updated

The Cystic Fibrosis Trust (stylised as Cystic Fibrosis) is a UK-based national charity founded in 1964, dealing with all aspects of cystic fibrosis (CF). It funds research to treat and cure CF and aims to ensure appropriate clinical care and support for people with cystic fibrosis.

Contents

Objectives

Its objectives are:

Research

The aim of the Cystic Fibrosis Trust research is to understand, treat and cure cystic fibrosis. The Cystic Fibrosis Trust is the major funder of medical and scientific CF research in the UK. The Trust's research falls into two main categories:

Clinical care

Cystic fibrosis is a complex disease requiring considerable specialist treatment. In the last fifteen years, the Trust has helped to set up and staff 45 specialist CF treatment centres throughout the UK. Since 1997, the Cystic Fibrosis Trust has invested over £10 million in the NHS to improve clinical care for the 8,000 people in the UK with CF; helping fund doctors, nurses and multidisciplinary teams.

The Cystic Fibrosis Trust sets the national standard on clinical care; provides and funds a UK CF Clinical Database; and measures levels of service provision. The Trust's Expert Patient Advisers (who all have CF) work with health providers and government to influence and improve the care of those with CF across the UK.

Information, advice and support

The Cystic Fibrosis Trust provides a confidential, 9–5 Monday to Friday helpline service for advice and support on all aspects of cystic fibrosis. The Trust also offers information and advice to those affected, along with their families and friends, schools and employers and anyone interested in cystic fibrosis. The Trust also advise families on benefits and, where appropriate, provides financial assistance and welfare grants.

Community support

The Cystic Fibrosis Trust receives donations and support from local communities. [2] In addition to the contributions, fundraising efforts have been undertaken by UK artist Jenny Wicks in 2009 with her photographic art exhibition, short documentary and book titled Root Ginger . The exhibition describes the recessive gene inheritance pattern that causes ginger, or red, hair – the same inheritance pattern that causes cystic fibrosis. [3] A portion of the proceeds from the exhibition and book sales will go to the Cystic Fibrosis Trust.

See also

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical field

Gene therapy is a medical technology which aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

<span class="mw-page-title-main">Cystic fibrosis</span> Autosomal recessive disease mostly affecting the lungs

Cystic fibrosis (CF) is a rare genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. Other signs and symptoms may include sinus infections, poor growth, fatty stool, clubbing of the fingers and toes, and infertility in most males. Different people may have different degrees of symptoms.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

<span class="mw-page-title-main">Cystic fibrosis transmembrane conductance regulator</span> Mammalian protein found in humans

Cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and anion channel in vertebrates that is encoded by the CFTR gene.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

<span class="mw-page-title-main">The Alfred Hospital</span> Hospital in Victoria, Australia

The Alfred Hospital, also known as The Alfred or Alfred Hospital, is a leading tertiary teaching hospital in Melbourne, Victoria. It is the second oldest hospital in Victoria, and the oldest Melbourne hospital still operating on its original site. The Alfred Hospital is one of two major adult trauma centres in Victoria, and houses the largest intensive care unit in Australia. In 2021 it was ranked as one of the world's best hospitals. It is located at the corner of Commercial and Punt Roads, Prahran, opposite Fawkner Park.

<span class="mw-page-title-main">Cystic Fibrosis Foundation</span> American non-profit organisation

The Cystic Fibrosis Foundation (CFF) is a 501(c)(3) non-profit organization in the United States established to provide the means to cure cystic fibrosis (CF) and ensure that those living with CF live long and productive lives. The Foundation provides information about cystic fibrosis and finances CF research that aims to improve the quality of life for people with the disease. The Foundation also engages in legislative lobbying for cystic fibrosis.

Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller III to describe an imaginative and risk-taking approach to philanthropy that may be undertaken by charitable organizations.

Jeans for Genes Day is a national fundraiser held in Australia and the United Kingdom. The two fundraisers are not associated with one another and raise money for different organisations.

<span class="mw-page-title-main">Foundation Fighting Blindness</span>

The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cures for the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness.

<span class="mw-page-title-main">Cystic Fibrosis Canada</span> Canadian not-for-profit corporation

Cystic Fibrosis Canada is a national charitable not-for-profit corporation established in 1960.

<span class="mw-page-title-main">Ivacaftor</span> Pharmaceutical medication used to treat cystic fibrosis

Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.

Physiotherapists treating patients following uncomplicated coronary artery bypass surgery surgery continue to use interventions such as deep breathing exercises that are not supported by best available evidence. Standardised guidelines may be required to better match clinical practice with current literature.

<span class="mw-page-title-main">Emily's Entourage</span>

Emily's Entourage is a nonprofit organization that raises money and awareness to help find a cure for rare ("nonsense") mutations of cystic fibrosis (CF), a genetic disorder that generally affects a person's lungs and digestive system. The foundation has raised over $1 million, largely from viral fundraising through universities and video campaigns. The organization also participates in exploratory research initiatives aimed at understanding and advancing towards a cure.

Robert Williamson is a retired British-Australian molecular biologist who specialised in the mapping, gene identification, and diagnosis of human genetic disorders.

Jane C. Davies is a British physician who is Professor of Paediatric Respirology at Imperial College School of Medicine. She is an Honorary Consultant at the Royal Brompton and Harefield NHS Foundation Trust.

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (EU), is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.

<span class="mw-page-title-main">Cystic fibrosis and race</span>

Underrepresented populations, especially black and hispanic populations with cystic fibrosis are often not successfully diagnosed. This is in part due to the minimal dissemination of existing data on patients from these underrepresented groups. While white populations do appear to experience a higher frequency of cystic fibrosis, other ethnicities are also affected and not always by the same biological mechanisms. Thus, many healthcare and treatment options are less reliable or unavailable to underrepresented populations. This issue affects the level at which public health needs are being met across the world.

References